Abemaciclib

Abemaciclib is an oral cyclin dependent kinase CDK4/6 inhibitor. In HR+ and HER2- breast cancer cells, CDK4 and CDK6 promote the phosphorylation of retinoblastoma protein (retinoblastomapChemicalbookrotein), and promote cell cycle progression and cell proliferation.

Abemaciclib can inhibit the phosphorylation of Rb and block the progression of cells from G1 phase to S phase of cell cycle, resulting in cell aging and apoptosis.

Abemaciclib and Fulvestrant were used in the treatment of HR positive, HER2 negative patients with advanced or metastatic breast cancer.